查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1864450

動脈粥狀硬化藥物市場依藥物類別、給藥途徑、通路、劑型及最終用戶分類－2025-2032年全球預測

Atherosclerosis Drugs Market by Drug Class, Administration Route, Distribution Channel, Dosage Form, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，動脈粥狀硬化藥物市場將成長至 375.7 億美元，複合年成長率為 5.85%。

主要市場統計數據
基準年 2024 238.2億美元
預計年份：2025年 252.5億美元
預測年份：2032年 375.7億美元
複合年成長率 (%) 5.85%

全面介紹影響現代動脈粥狀硬化治療方法的臨床創新、監管趨勢和營運壓力

動脈粥狀硬化治療領域融合了數十年的臨床經驗和生物醫學創新浪潮，正在重新定義臨床醫生和醫療保健系統管理血脂和降低心血管風險的方式。生技藥品、標靶治療和製劑科學的進步與長期使用的口服藥物並存，為臨床醫生建構了一套複雜的治療工具。同時，監管、證據標準和支付方的期望也在不斷變化，影響哪些干預措施能夠被納入配藥清單和臨床實踐。在此背景下，商業和臨床相關人員必須應對錯綜複雜的臨床結果資料、安全性概況、生產考量和進入限制等諸多因素。

深入探討正在重塑動脈粥狀硬化藥物治療策略和商業性動態的技術進步、支付方期望以及不斷演變的給藥模式。

在科學突破和醫療服務模式不斷發展的推動下，動脈粥狀硬化藥物領域正經歷著變革性的轉變。精準標靶化脂質代謝通道和單株抗體療法的出現正在改變治療模式，促使臨床醫生考慮新的治療順序和聯合治療策略。同時，數位健康工具和遠端監測正在提高患者依從性，並實現更精細的風險分層，從而影響治療方案的選擇和管理。

對 2025 年修訂的美國關稅如何重塑動脈粥狀硬化藥物價值鏈的供應鏈韌性、籌資策略和商業規劃進行策略分析。

2025年美國關稅調整對動脈粥狀硬化藥物生態系統產生了多方面的影響，包括原料採購、生產決策和跨境分銷策略。關稅調整凸顯了供應鏈本地化和雙重籌資策略的重要性，以應對成本波動和合規性問題。製造商正在透過重新評估供應商合約、尋找替代供應商，以及在某些情況下將生產轉移到貿易條款更可預測的地區來應對這些變化。

將藥物類別特徵、給藥途徑、劑型、分銷管道和最終用戶環境與商業和臨床應用模式聯繫起來的詳細細分分析

細分市場分析揭示了不同藥物類別和給藥途徑在臨床、營運和商業性動態方面存在顯著差異。在各類藥物中，膽汁酸螯合劑，例如考來烯胺、考來維崙和考來替泊，仍被廣泛應用，其長期使用取決於耐受性和患者依從性。同時，貝特類藥物，包括非諾貝特和吉非貝齊，針對特定的血脂亞譜，在以降低三酸甘油酯為首要目標的臨床環境中仍扮演著重要角色。菸鹼酸，無論是緩釋性或速釋製劑，其獨特的耐受性和劑量考量都會影響患者的選擇。此外， Omega-3脂肪酸，以其二十二碳六烯酸 (DHA) 和二十碳五烯酸 (EPA) 的特徵為特徵，被定位為輔助性治療，其在特定適應症方面的證據正在不斷積累。 PCSK9抑制劑，例如阿利西尤單抗和依洛尤單抗，已經改變了高強度低密度脂蛋白膽固醇 (LDL-C) 管理策略，尤其適用於口服治療未能達到目標的患者。同時，由於其廣泛的證據基礎和已確立的安全特性，他汀類藥物（包括Atorvastatin、普伐他汀、rosuvastatin和Simvastatin）繼續構成降血脂治療的基石。

區域競爭和監管差異將導致美洲、歐洲、中東和非洲以及亞太地區出現不同的准入策略、證據優先事項和商業性方法。

區域趨勢將以不同的方式影響美洲、歐洲、中東和非洲以及亞太地區的臨床實踐、監管管道和商業性准入。在美洲，既定的臨床指南和整合的支付方-服務提供方結構支持循證干預措施，而區域監管和報銷管道則鼓勵關注真實世界的有效性和長期安全性。相較之下，歐洲、中東和非洲的法規結構和報銷環境各不相同，各國不同的價格談判和衛生技術評估流程導致實施時間和進入策略有差異。

競爭策略、製造差異化和夥伴關係模式定義了那些在動脈粥狀硬化領域提供持續臨床和商業性價值的組織。

領先的動脈粥狀硬化治療主要企業正在推行多元化策略，力求在創新、生命週期管理和業務永續營運之間取得平衡。現有企業持續投資於產品改進、緩釋性和聯合治療，以提高患者依從性和治療效果；而專業公司則專注於高價值生技藥品和標靶治療，以應對持續存在的殘餘風險。策略聯盟、授權協議和共同開發契約在尋求縮短產品上市時間、實現產品線多元化和共用研發風險的公司中日益普遍。

為加速產品推廣和普及，提出切實可行的策略建議，旨在整合臨床證據、供應鏈韌性和以支付方為中心的商業性執行。

產業領導者應採取整合臨床差異化、切實可行的商業性執行和營運韌性的策略。首先，為滿足監管機構和支付方的要求，應優先進行證據生成工作，兼顧隨機對照試驗的嚴謹性和真實世界療效，投資於註冊研究和縱向研究，以證明臨床終點和長期耐受性方面的顯著改善。其次，透過雙重採購、選擇性地域多角化生產和增強貿易合規能力來最佳化供應鏈設計，從而降低關稅波動和物流中斷的影響。第三，利用跨藥物類別、給藥途徑、劑型、分銷管道和終端用戶環境的細分洞察，調整產品定位，使其與治療屬性、臨床路徑和支付方要求相符。

我們採用透明的混合方法研究框架，將主要專家見解與次要證據綜合相結合，以嚴格描繪臨床、商業性和營運動態。

本分析的調查方法融合了定性和定量方法，以確保證據基礎的穩健性和透明度。主要研究包括對臨床醫生、支付方代表、供應鏈經理和行業高管進行專家訪談，以收集關於臨床實踐、報銷促進因素和營運限制的細緻觀點。次要研究整合了同儕審查文獻、監管指導文件、臨床實驗室註冊資訊和公共衛生資料檢驗臨床療效、安全性訊號和指南演變。數據三角驗證確保研究結果既反映了對照試驗的證據，也反映了真實世界的經驗。

簡而言之，臨床創新、支付方期望和營運韌性是支撐成功的動脈粥狀硬化藥物策略的支柱。

摘要，動脈粥狀硬化藥物領域的特點是持續性口服療法與不斷發展的生技藥品之間動態的相互作用，而這種相互作用又受到不斷變化的監管預期和商業性現實的影響。臨床創新正在拓展臨床醫生可選擇的治療方案，但藥物的普及應用取決於令人信服的真實世界數據、與支付共用的價值認知以及供應鏈的韌性。從生產策略到分銷管道最佳化，營運靈活性將日益決定哪些治療方法能夠獲得廣泛且持續的應用。那些能夠將科學差異化、務實的商業性執行以及積極的支付方溝通相結合的相關人員，將更有能力在控制成本和應對准入壓力的同時，改善患者的治療效果。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • PCSK9抑制劑對動脈粥狀硬化治療中競爭性定價和市場擴張的影響
  • siRNA療法標靶降低脂蛋白(a)在動脈粥狀硬化治療的臨床進展
  • 擴大貝培多酸和他汀類藥物聯合治療的適用範圍可提高患者遵從性和治療效果。
  • 口服PCSK9抑制劑為動脈粥狀硬化的治療提供了注射生技藥品的創新替代方案。
  • 透過採用基因譜分析和個人化醫療策略，最佳化動脈粥狀硬化藥物治療方案，以適應個別患者的需求。
  • 將數位健康平台與遠端監測結合，以提高動脈粥狀硬化藥物治療方案的依從性
  • 生物類似單株抗體市場進入對動脈粥狀硬化生技藥品療法的成本效益和可及性的影響

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 動脈粥狀硬化藥物市場（依藥物類別分類）

  • 膽汁酸螯合劑
    • 考來烯胺
    • 科爾塞維拉姆
    • 科萊斯蒂波爾
  • 貝特類藥物
    • 非諾貝特
    • 吉非貝齊
  • 菸鹼酸
    • 緩釋性
    • 立即發布
  • Omega-3脂肪酸
    • 二十二碳六烯酸
    • 二十碳五烯酸
  • PCSK9抑制劑
    • 阿利西尤單抗
    • 依洛尤單抗
  • 他汀類藥物
    • Atorvastatin
    • 普伐他汀
    • rosuvastatin
    • Simvastatin

9. 依給藥途徑分類的動脈粥狀硬化藥物市場

  • 注射
    • 靜脈注射
  • 口服
    • 膠囊
    • 藥片

10. 動脈粥狀硬化藥物市場依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 動脈粥狀硬化藥物市場（依劑型分類）

  • 膠囊
  • 注射
  • 藥片

第12章 動脈粥狀硬化藥物市場（依最終用戶分類）

  • 診所
  • 居家照護
  • 醫院

13. 各地區動脈粥狀硬化藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 動脈粥狀硬化藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國動脈粥狀硬化藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Amgen Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • AstraZeneca PLC
    • Regeneron Pharmaceuticals, Inc.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Bayer AG
    • Johnson & Johnson
Product Code: MRR-F97DD5A7DBFE

The Atherosclerosis Drugs Market is projected to grow by USD 37.57 billion at a CAGR of 5.85% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 23.82 billion
Estimated Year [2025] USD 25.25 billion
Forecast Year [2032] USD 37.57 billion
CAGR (%) 5.85%

A comprehensive introduction outlining clinical innovations, regulatory dynamics, and operational pressures shaping modern therapeutic approaches to atherosclerosis

The therapy landscape for atherosclerosis blends decades of clinical experience with a wave of biomedical innovation that is redefining how clinicians and health systems approach lipid management and cardiovascular risk reduction. Advances in biologics, targeted therapies, and formulation science coexist with long-established oral agents, creating a complex therapeutic toolkit for clinicians. Meanwhile, regulatory scrutiny, evidence standards, and payer expectations continue to evolve, shaping which interventions gain traction in formularies and clinical practice. In this environment, commercial and clinical stakeholders must navigate a confluence of clinical outcomes data, safety profiles, manufacturing considerations, and access constraints.

In practice, care pathways are being reframed by precision medicine approaches, greater emphasis on real-world evidence, and a growing focus on long-term safety and tolerability in at-risk populations. These forces create opportunities for differentiated products that demonstrate meaningful clinical benefit, adherence advantages, or logistical efficiencies. At the same time, operational pressures such as supply chain resilience, pricing negotiations, and integration into multidisciplinary care teams influence how therapies are adopted and maintained. By synthesizing clinical trends with operational realities, stakeholders can identify strategic windows for product differentiation, lifecycle management, and partnership-driven expansion.

An in-depth exploration of technological advances, payer expectations, and delivery model evolution that are reshaping therapeutic strategies and commercial dynamics in atherosclerosis care

The landscape of atherosclerosis therapy is undergoing transformative shifts driven by scientific breakthroughs and evolving healthcare delivery models. Precision targeting of lipid pathways and the emergence of monoclonal antibody therapeutics have altered treatment paradigms, prompting clinicians to consider new sequencing and combination strategies. Concurrently, digital health tools and remote monitoring are improving patient adherence and enabling more nuanced risk stratification, which in turn affects treatment selection and longitudinal management.

Commercial models are also shifting as payers demand robust real-world outcomes and value-based arrangements that tie payment to demonstrable clinical benefit. Manufacturers are adapting by focusing on differentiated formulations, patient-support programs, and evidence generation beyond randomized controlled trials. Supply chain innovations and strategic manufacturing partnerships are helping to mitigate production bottlenecks for complex biologics while ensuring continuity of access for generic oral agents. Taken together, these changes are redefining competitive dynamics and creating pathways for both established and emerging therapies to deliver sustained clinical value in practice.

A strategic analysis of how revised United States tariff measures in 2025 have reshaped supply chain resilience, procurement strategy, and commercial planning across the atherosclerosis drug value chain

United States tariff policy changes in 2025 have produced layered effects across the atherosclerosis drug ecosystem, influencing raw material sourcing, manufacturing decisions, and cross-border distribution strategies. Tariff adjustments have increased the importance of supply chain localization and dual-sourcing strategies to manage cost volatility and regulatory compliance. Manufacturers have responded by reassessing supplier contracts, qualifying alternative vendors, and in some cases reallocating production footprints to jurisdictions with more predictable trade terms.

These trade-policy dynamics have also shaped commercial negotiations and pricing constructs, with payers and providers recalibrating procurement strategies to manage downstream cost pressures. For complex biologics and novel agents that rely on specialized components or high-value active pharmaceutical ingredients, tariff-driven cost increases have incentivized investments in vertical integration and long-term contracting. Meanwhile, established oral therapies with mature manufacturing bases have leaned into scale efficiencies and optimized logistics to preserve supply continuity.

Operationally, increased customs scrutiny and variability in duty assessments have elevated the role of trade compliance expertise within life sciences organizations. In response, teams have expanded scenario planning and stress-testing to understand how tariff permutations affect product launch timelines, portfolio prioritization, and global distribution choices. As a result, organizations that align regulatory strategy, procurement, and commercial planning are better positioned to navigate the cumulative impact of trade policy shifts without disrupting patient access and care delivery.

Granular segmentation insights linking drug class nuances, administration routes, dosage forms, distribution channels, and end-user settings to commercial and clinical adoption patterns

Segment-level insights reveal differentiated clinical, operational, and commercial dynamics across drug classes and modalities. Within drug classes, bile acid sequestrants such as cholestyramine, colesevelam, and colestipol continue to occupy a role where tolerability and adherence considerations determine long-term use, while fibrates including fenofibrate and gemfibrozil address specific lipid subprofiles and remain clinically relevant where triglyceride reduction is prioritized. Niacin in extended release and immediate release formulations presents distinct tolerability and dosing considerations that affect patient selection, and omega-3 fatty acids characterized by docosahexaenoic acid and eicosapentaenoic acid profiles are positioned as adjunctive options with evolving evidence for specific indications. PCSK9 inhibitors represented by alirocumab and evolocumab have altered high-intensity LDL management strategies, especially where patients do not reach targets with oral agents, and statins including atorvastatin, pravastatin, rosuvastatin, and simvastatin continue to form the backbone of lipid-lowering regimens given their broad evidence base and established safety profiles.

Administration routes and dosage forms further influence adoption and logistics. Injectable therapies, including those administered intravenously, demand distinct clinic workflows, cold-chain logistics, and patient-support programs, whereas oral therapies in capsule and tablet formats prioritize adherence support and simplifying regimens for ambulatory settings. Distribution channel dynamics show divergent opportunities across hospital pharmacy, online pharmacy, and retail pharmacy environments, with each channel presenting unique payer contracting considerations and patient access pathways. Dosage forms categorized as capsule, injection, and tablet intersect with end-user settings such as clinic, home care, and hospital to create nuanced adoption patterns where clinical setting, patient capability, and reimbursement frameworks determine the optimal therapeutic choice. These segmentation lenses collectively inform product positioning, lifecycle strategies, and commercial execution plans across varied healthcare delivery contexts.

Regional competitive and regulatory nuances that drive differentiated access strategies, evidence priorities, and commercial approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape clinical practice, regulatory pathways, and commercial access in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, well-established clinical guidelines and integrated payer-provider structures favor evidence-rich interventions, and regional regulatory and reimbursement pathways drive emphasis on real-world effectiveness and long-term safety. Conversely, Europe, Middle East & Africa present heterogeneous regulatory frameworks and reimbursement environments where country-level pricing negotiations and health technology assessment processes create varied adoption timelines and differentiated access strategies.

Asia-Pacific markets display a mix of rapid innovation adoption in select urban healthcare systems alongside broad demand for cost-effective oral therapies across diverse care settings. Regional manufacturing hubs and local regulatory reforms have encouraged regional supply chain optimization and in-market manufacturing partnerships. Across all regions, local clinical practice patterns, demographic risk profiles, and health system funding models influence which therapies gain traction, how patient support programs are structured, and where investments in real-world evidence generation will have the greatest impact. Consequently, regional commercial strategies must align regulatory engagement, pricing approaches, and evidence development to regional priorities in order to maximize clinical uptake and sustainable access.

Competitive corporate strategies, manufacturing differentiation, and partnership models that are defining which organizations deliver sustained clinical and commercial value in the atherosclerosis domain

Leading companies in the atherosclerosis space are pursuing multi-pronged strategies that balance innovation with lifecycle management and operational resilience. Established players continue to invest in incremental product improvements, extended-release formulations, and combination approaches that enhance adherence and therapeutic effect, while specialty firms focus on high-value biologics and targeted agents that address persistent residual risk. Strategic alliances, licensing arrangements, and co-development agreements are increasingly common as organizations seek to accelerate time to market, diversify pipelines, and share development risk.

Manufacturing and supply chain capabilities emerge as critical differentiators, especially for complex injectables and monoclonal antibodies that require specialized production infrastructure and stringent cold-chain logistics. Companies that integrate manufacturing planning with commercial forecasting and regulatory strategy secure improved launch readiness and continuity of supply. Moreover, an intensified focus on value demonstration has prompted greater investment in post-launch studies, registries, and outcomes research to support payer engagement. Finally, digital health partnerships and patient support ecosystems are being leveraged to improve adherence, monitor safety signals, and strengthen real-world value propositions, reinforcing a shift toward holistic product offerings rather than standalone molecules.

Actionable strategic recommendations for aligning clinical evidence, supply chain resilience, and payer-focused commercial execution to accelerate product adoption and access

Industry leaders should adopt an integrated strategy that aligns clinical differentiation with pragmatic commercial execution and operational resilience. First, prioritize evidence generation that balances randomized trial rigor with real-world outcomes to satisfy both regulatory bodies and payers; invest in registries and longitudinal studies that demonstrate meaningful improvement in clinical endpoints and long-term tolerability. Second, optimize supply chain design through dual sourcing, selective regionalization of manufacturing, and strengthened trade compliance capabilities to mitigate the impact of tariff volatility and logistical disruptions. Third, tailor product positioning by leveraging segmentation insights across drug class, administration route, dosage form, distribution channel, and end-user setting to match therapeutic attributes to clinical pathways and payer requirements.

Further, pursue partnerships that accelerate access and broaden care delivery channels, integrating digital adherence solutions and patient-support services to enhance persistence and outcomes. Engage early with payers to explore value-based arrangements and to co-develop evidence that aligns with reimbursement criteria. Finally, invest in commercial capability building-equipping field teams with outcomes-driven messaging, payer-engagement tools, and localized launch playbooks-to ensure that clinical advantages translate into sustained uptake across diverse healthcare settings. Taken together, these approaches will help organizations navigate complexity while maximizing patient benefit and commercial performance.

A transparent mixed-methods research framework combining primary expert insight and secondary evidence synthesis to rigorously map clinical, commercial, and operational dynamics

The research methodology underpinning this analysis integrates qualitative and quantitative approaches to ensure a robust, transparent evidence base. Primary research components include expert interviews with clinicians, payer representatives, supply chain leaders, and industry executives to capture nuanced perspectives on clinical practice, reimbursement drivers, and operational constraints. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public health datasets to validate clinical efficacy, safety signals, and guideline evolution. Data triangulation ensured that insights reflect both controlled trial evidence and real-world experience.

Analytical frameworks employed include segmentation mapping across therapeutic class, administration route, distribution channel, dosage form, and end-user setting to identify adoption patterns and unmet needs. Scenario analysis and sensitivity testing were used to explore how variations in trade policy, reimbursement criteria, and supply chain disruptions affect strategic priorities. Quality assurance procedures included cross-validation of interview findings with literature evidence and iterative expert review to refine conclusions. This mixed-methods approach produces an actionable synthesis that stakeholders can apply to clinical development strategy, market access planning, and operational decision-making while maintaining methodological rigor and reproducibility.

A concise conclusion synthesizing clinical innovation, payer expectations, and operational resilience as the pillars for successful atherosclerosis therapy strategies

In sum, the atherosclerosis therapeutic arena is defined by a dynamic interplay between enduring oral therapies and advancing biologics, underpinned by shifting regulatory expectations and commercial realities. Clinical innovation is expanding the toolkit available to clinicians, but adoption depends on convincing real-world evidence, payer-aligned value demonstrations, and supply chain robustness. Operational agility-from manufacturing strategy to distribution channel optimization-will increasingly determine which therapies achieve broad, sustained use. Stakeholders that blend scientific differentiation with pragmatic commercial execution and proactive payer engagement will be best positioned to improve patient outcomes while managing cost and access pressures.

As the environment continues to evolve, decision-makers should emphasize evidence generation that resonates with payers and clinicians, develop resilient supply networks that insulate launches from trade perturbations, and tailor regional strategies to local regulatory and clinical contexts. By doing so, organizations can convert clinical promise into tangible improvements in cardiovascular risk management and construct durable commercial advantages that support future innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Impact of PCSK9 inhibitors on competitive pricing and market expansion in atherosclerosis treatment
  • 5.2. Clinical progress of siRNA therapies targeting lipoprotein(a) reduction in atherosclerosis management
  • 5.3. Expansion of combination regimens with bempedoic acid and statins to enhance patient adherence and outcomes
  • 5.4. Emergence of oral PCSK9 inhibitors as a disruptive alternative to injectable biologics in atherosclerosis care
  • 5.5. Adoption of genetic profiling and personalized medicine strategies to tailor atherosclerosis drug therapies to individual patients
  • 5.6. Integration of digital health platforms and remote monitoring to improve adherence in atherosclerosis pharmacotherapy programs
  • 5.7. Impact of biosimilar monoclonal antibody entries on affordability and access to atherosclerosis biologic therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Atherosclerosis Drugs Market, by Drug Class

  • 8.1. Bile Acid Sequestrants
    • 8.1.1. Cholestyramine
    • 8.1.2. Colesevelam
    • 8.1.3. Colestipol
  • 8.2. Fibrates
    • 8.2.1. Fenofibrate
    • 8.2.2. Gemfibrozil
  • 8.3. Niacin
    • 8.3.1. Extended Release
    • 8.3.2. Immediate Release
  • 8.4. Omega-3 Fatty Acids
    • 8.4.1. Docosahexaenoic Acid
    • 8.4.2. Eicosapentaenoic Acid
  • 8.5. PCSK9 Inhibitors
    • 8.5.1. Alirocumab
    • 8.5.2. Evolocumab
  • 8.6. Statins
    • 8.6.1. Atorvastatin
    • 8.6.2. Pravastatin
    • 8.6.3. Rosuvastatin
    • 8.6.4. Simvastatin

9. Atherosclerosis Drugs Market, by Administration Route

  • 9.1. Injectable
    • 9.1.1. Intravenous
  • 9.2. Oral
    • 9.2.1. Capsule
    • 9.2.2. Tablet

10. Atherosclerosis Drugs Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Atherosclerosis Drugs Market, by Dosage Form

  • 11.1. Capsule
  • 11.2. Injection
  • 11.3. Tablet

12. Atherosclerosis Drugs Market, by End User

  • 12.1. Clinic
  • 12.2. Home Care
  • 12.3. Hospital

13. Atherosclerosis Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Atherosclerosis Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Atherosclerosis Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Amgen Inc.
    • 16.3.2. Novartis AG
    • 16.3.3. Pfizer Inc.
    • 16.3.4. Sanofi S.A.
    • 16.3.5. AstraZeneca PLC
    • 16.3.6. Regeneron Pharmaceuticals, Inc.
    • 16.3.7. Merck & Co., Inc.
    • 16.3.8. Bristol-Myers Squibb Company
    • 16.3.9. Bayer AG
    • 16.3.10. Johnson & Johnson

LIST OF FIGURES

  • FIGURE 1. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ATHEROSCLEROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ATHEROSCLEROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ATHEROSCLEROSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET